Back to search results

Hyperpolarized 129Xenon MRI for Interstitial Lung Disease

This study is testing a new way to look at how your lungs work using a special type of MRI with Hyperpolarized 129Xenon Gas. This gas helps doctors see how air moves in your lungs, how lung tissues are structured, and how gas transfers into your blood. This imaging technique aims to provide a more detailed view of lung function, especially for conditions like Interstitial Lung Disease. The study will enroll 445 participants, including healthy individuals and those with diagnosed lung conditions. The main goal is to check the safety and tolerability of the Hyperpolarized 129Xenon Gas by tracking any side effects up to Day 2 after administration.

Study design
This interventional study plans to enroll 445 participants. It is not specified if it is randomized or blinded.
What's involved
You would inhale Hyperpolarized 129Xenon Gas in multiple doses, tailored to your lung capacity, and hold your breath for up to 15 seconds after each dose.
Compensation
Not stated in the trial record.
Follow-up
The study will track adverse events (side effects) up to Day 2 after the intervention.

AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.

NCT01280994

Hyperpolarized 129Xe MRI for Imaging Pulmonary Function

Recruiting
PHASE2Ages 18+InterventionalDiagnostic
Bastiaan Driehuys
~445 participants
Updated 2026-01-16 on ClinicalTrials.gov
What's tested:Hyperpolarized 129Xenon Gas

At a glance

Recruiting sites
1 of 1 listed site is recruiting right now
RecruitingSuspended, closed, or not yet open
What they're measuring
Number of Participants with Adverse Events as a Measure of Safety and Tolerability
Measured over Day 2

Conditions

Interstitial Lung Disease

Explore related trials

Interstitial Lung DiseaseLung Disorder

Where it's being run

1 sites across 1 states
North Carolina1

Study leadership

  • Joseph Mammarappallil, M.D. · PRINCIPAL_INVESTIGATOR · Duke University

Who to contact

Jennifer Korzekwinski
[email protected]
919-681-7362
Email the study team

Opens a ready-to-send draft in your own email app — review before sending.

What this trial measures

  • Number of Participants with Adverse Events as a Measure of Safety and TolerabilityDay 2

    The purpose of this trial is to examine the ability of HP 129Xe imaging to characterize the lung in healthy and diseased states. The safety endpoint for each subject is to record any adverse events as a measure of safety and tolerability. The technical endpoint for each subject is the acquisition of technically adequate HP 129Xe MR images.